Blood Plasma Derivatives Market Research Report- Global Forecast To 2023

Report / Search Code: MRFR/Pharma/0817-HCRR  Publish Date: November, 2018

Description:

Global Blood Plasma Derivatives Information by type (Albumin, Anti-Thrombin III, Intravenous immunoglobulin (IVIG), Fresh Frozen Plasma (FFP) and others), by application (Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, and others), by end users (Hospitals, clinics, diagnostic centers, blood transfusion centers and others- Forecast to 2023

Market Scenario:

Blood plasma derivatives have a wide range of applications thus increasing their demand in the market. They are used in various diseases like HIV, hepatitis B and Hepatitis C. Plasma derivatives are collected from large number of donors for their use in patients suffering from life threatening diseases. Hence the importance of blood plasma derivatives have increased in healthcare. The global market of Blood Plasma Derivatives is expected to reach US$ 58.2 billion in 2023 from US$ 30.5 billion in 2016 with a CAGR of approximately 7.52% during the forecast period 2017-2023.

Study Objectives:

Main objective of this research is to provide information about types of derivative of plasma, its application and its end users

- To provide detailed analysis of the market structure along with forecast for the next six years of the various segments and sub-segments of the Blood Plasma Derivatives market.
- To provide insights about factors affecting the market growth.
- To analyze the Blood Plasma Derivatives market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- America, Europe, Asia-Pacific and Middle East and Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective.
- To provide country level analysis of the market for segments by type of plasma derivatives, by application, by end users and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Blood Plasma Derivatives market.

Intended Audience

- Blood Plasma Derivatives Companies
- Research and Development (R&D) Companies
Medical Research Laboratories
Diagnostic centers
Blood transfusion centers
Academic Medical Institutes and Universities

Figure 1: Research methodology:

Figure 2: Market Synopsis of Blood Plasma Derivatives Market by type, 2016 (%):

Segments:
Global Blood Plasma Derivatives market has been segmented on the basis of type which includes albumin, anti-thrombin, intravenous immunoglobulin (IVIG), fresh frozen plasma (FFP) and others. Others types are Factor VII, Factor IX and Alpha 1 proteinase inhibitor concentrate. On the basis on application the market is segmented into Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, and others. Other application includes Von Willebrand disease. End users include hospitals, clinics, diagnostic centers, blood transfusion centers and others.

Regional Analysis of Blood Plasma Derivatives Market:
Globally, Blood Plasma Derivatives market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa. North America is the largest market for syringe and needle. The North American market for Blood Plasma Derivatives is expected to grow at a CAGR of 4.25% which is expected to reach at US$ 35.50 billion from US$ 20 billion in 2016 by the end of the forecasted period. Awareness regarding use of plasma derivatives for patients suffering from infectious diseases drive this market in North America. Europe is the second-largest market for Blood Plasma Derivatives which is expected to grow at a CAGR of 3.8%. Extensive research on safe blood
transfusion in healthcare organizations and research laboratories favor the growth of this market in Europe. Whereas Asia Pacific is expected to be the fastest growing market for Blood Plasma Derivatives market. India is expected to be the emerging and fastest growing market. Demand for plasma derivatives for inactivation of HIV favor the demand of plasma derivatives in Asia-pacific. The market shows steady growth in Middle East and Africa.

Key Players for Blood Plasma Derivatives Market:

Some of the key players in this market are: Grifols (Germany), SK Plasma (Korea), Fusion Healthcare (India), Baxter International Inc. (U.S), CSL Limited (Australia).

Other players in this market are Octapharma AG (Germany), Biotest AG (Germany), Bain Capital (U.S).

The report for Blood Plasma Derivatives market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

Contents:

Table of Contents

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.1.1 Increasing incidences of infectious diseases

4.1.2 Increasing awareness use of blood plasma derivatives in HIV

4.2 Restraints

4.2.1 Safety concerns during blood transfusion

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining power of suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6 Global Blood Plasma Derivatives market by type

6.1 Albumin
6.2 Anti-Thrombin III
6.3 Intravenous immunoglobulin (IVIG)
6.4 Fresh Frozen Plasma (FFP)
6.5 Others
6.5.1 Factor VII
6.5.2 Factor IX
6.5.3 Alpha 1 proteinase inhibitor concentrate

7. Global Blood Plasma Derivatives market by application
7.1 Hemophilia A
7.2 Hemophilia B
7.3 HIV
7.4 Hepatitis B
7.5 Hepatitis C
7.6 Thrombocytosis
7.7 Others
7.7.1 Von Willebrand disease

8. Global Blood Plasma Derivatives market by end users
8.1 Hospitals
8.2 Clinics
8.3 Diagnostic Centres
8.4 Blood transfusion centres
8.5 Others

9. Global Blood Plasma Derivatives market by region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.2 Mexico
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.3.2.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Australia
9.4.6 Rest of Asia
9.5 Middle East and Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Turkey
9.5.4 Rest of Middle East and Africa

10 Competitive Landscape
10.1 Pricing of ventilators
10.2 Production Capacity of Major Players

11 Company Profile
11.1 Grifols
11.1.1 Overview
11.1.2 Product/Business Segment Overview
11.1.3 Financial Updates
11.1.4 Key Developments
11.2 SK Plasma
11.2.1 Overview
11.2.2 Product/Business Segment Overview
11.2.3 Financial Updates
11.2.4 Key Developments
11.3 Fusion Healthcare
11.3.1 Overview
11.3.2 Product/Business Segment Overview
11.3.3 Financial Updates
11.4 Baxter International Inc.
11.4.1 Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Updates
11.4.4 Key Development
11.5 CSL Limited
11.5.1 Overview
11.5.2 Product/Business Segment Overview
11.5.3 Financial Updates
11.5.4 Key Developments
11.6 Octapharma AG
11.6.1 Overview
11.6.2 Product/Business Segment Overview
11.6.3 Financial Updates
11.6.4 Key Developments

11.7 Biotest AG
11.7.1 Overview
11.7.2 Product/Business Segment Overview
11.7.3 Financial Updates
11.7.4 Key Developments

11.8 Others